Alder BioPharmaceuticals (ALDR) Receives Daily Coverage Optimism Rating of 0.23
News stories about Alder BioPharmaceuticals (NASDAQ:ALDR) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alder BioPharmaceuticals earned a news impact score of 0.23 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.0086953023046 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Alder BioPharmaceuticals (ALDR) opened at 12.25 on Friday. The firm has a 50-day moving average price of $9.64 and a 200 day moving average price of $15.75. Alder BioPharmaceuticals has a 52-week low of $8.60 and a 52-week high of $34.64. The stock’s market cap is $829.48 million.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.67) by $0.19. The company had revenue of $0.68 million for the quarter. During the same period in the previous year, the business posted ($0.79) earnings per share. The firm’s quarterly revenue was up 518.2% compared to the same quarter last year. On average, analysts forecast that Alder BioPharmaceuticals will post ($5.60) earnings per share for the current fiscal year.
Several equities research analysts have recently commented on ALDR shares. Zacks Investment Research upgraded Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, July 11th. Credit Suisse Group downgraded Alder BioPharmaceuticals from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $30.00 to $17.00 in a report on Wednesday, June 28th. Mizuho restated a “buy” rating and set a $32.00 price objective on shares of Alder BioPharmaceuticals in a report on Friday, September 15th. Wells Fargo & Company restated an “outperform” rating and set a $51.00 price objective on shares of Alder BioPharmaceuticals in a report on Wednesday, June 28th. Finally, BMO Capital Markets restated an “outperform” rating and set a $27.00 price objective (down previously from $39.00) on shares of Alder BioPharmaceuticals in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $29.86.
COPYRIGHT VIOLATION NOTICE: “Alder BioPharmaceuticals (ALDR) Receives Daily Coverage Optimism Rating of 0.23” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/alder-biopharmaceuticals-aldr-receives-daily-coverage-optimism-rating-of-0-23/1598498.html.
In related news, Director Stephen M. Dow acquired 25,000 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Tuesday, July 18th. The stock was bought at an average price of $10.00 per share, with a total value of $250,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 10.60% of the stock is owned by company insiders.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.